HOME >> BIOLOGY >> NEWS
New, non-radioactive screen for antimalarial compounds

Panama City, Panama, Feb. 16, 2004--Panama's International Cooperative Biodiversity Group (ICBG) announces the development of a new test for identification of antimalarial compounds with wide applicability in the developing world. The assay for plant-derived compounds also can be used to detect anti-plasmodial compounds from synthetic or natural sources. Initial results of the research are published in the American Journal of Tropical Medicine and Hygiene under the title "A Novel DNA-Based Microfluorometric Method to Evaluate Antimalarial Drug Activity".

The assay is based on fluorochrome binding to parasite double stranded DNA. Pico Green, a powerful fluorochrome developed by Invitrogen Corporation's Molecular Probes business enables detection of the malaria parasite in cell culture without the need for radioactive materials used in current methods. The new assay will be attractive in developing countries where access and disposal of radioactive tracers is prohibitively expensive as well as in the many developed-world labs that prefer non-radioactive reagents.

The new method will be attractive to researchers because it is relatively inexpensive, easy to implement in biodiverse developing countries and most importantly, safe according to Yolanda Corbett who developed the assay in Dr. Eduardo Ortega's lab: "A fluorescent DNA probe is safer and is a novel approach in the sense that red blood cells don't have DNA, so we could quantify the parasite in microtiter plates."

Malaria kills more than a million people each year in Africa alone and threatens nearly 40 percent of the world's population. The major impediment to malaria control is the cost and distribution of antimalarial drugs. Every year, antimalarial treatments become less effective as drug resistant strains of the malaria parasite develop, making the discovery of new antimalarials essential in this fight against the disease.

"The most important aspect of the wo
'"/>

Contact: Beth King
kingb@tivoli.si.edu
202-786-2094 x8216
Smithsonian Tropical Research Institute
16-Feb-2004


Page: 1 2 3

Related biology news :

1. March of Dimes statement on newborn screening report
2. Virus known for its photo ops makes its movie screen debut
3. Only 21 states offer newborn screening tests recommended by March of Dimes
4. New screening method turns up potential compound for treating anthrax
5. Gene-based screen sorts cancer cases, say Stanford researchers
6. Genome-wide screen reveals new tricks of old genes
7. Genetic screening study at Stanford IDs most aggressive adult leukemia strains
8. Genetic screening recommended to detect new neurodegenerative disorder in men over age 50
9. HPV testing could be future strategy for primary screening for cervical cancer
10. Newborn screening for certain genetic disorders has benefits and some drawbacks
11. UCSD scientists develop novel way to screen molecules

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New non radioactive screen for antimalarial compounds

(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 ... of Debiopharm Group ™ , a Swiss-based global ... unmet medical needs as well as companion ... the investigational compounds Debio 1143 (SMAC mimetic) and ... at the 2015 Annual meeting of the ...
(Date:4/16/2015)... Washington (PRWEB) April 16, 2015 ... Applied Cancer Science and Resolution Bioscience, Inc. today ... to co-develop a novel, blood-based, clinic ready, Next ... cancer (NSCLC). The collaboration is the first to ... RET, and ROS1 fusions in blinded plasma samples ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
Cached News: